Meeting
2018 ASCO Annual Meeting
Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.
Authors
Michael Friedlander
Department of Medical Oncology, Prince of Wales Hospital, Sydney, New South Wales, Australia
Michael Friedlander , John K. Chan , Jim Java , Deborah K Armstrong , Maurie Markman , Thomas J. Herzog , Bradley J. Monk , Floor Jenniskens Backes , Angeles Alvarez Secord , Albert J. Bonebrake , Peter Graham Rose , Krishnansu Sujata Tewari , Robert S. Mannel , Samuel S. Lentz , Melissa Ann Geller , Larry J. Copeland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5556)
DOI
10.1200/JCO.2018.36.15_suppl.5556
Abstract #
5556
Poster Bd #
283
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
How long have we got? The accuracy of physicians’ estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC).
First Author: Felicia Roncolato
Poster
2019 Gastrointestinal Cancers Symposium
Characteristics of long-term survivors in stage III gastric cancer patients.
First Author: Youjin Jang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prognostic value of tumor budding in patients with stage II and III colon cancer: A single-institution experience.
First Author: David Viñal
Poster
2022 ASCO Annual Meeting
OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts.
First Author: Frederic Selle